The European Medicines Agency (EMA) has already appointed a rapporteur to conduct a gradual review of the Russian Sputnik V vaccine. This was reported on the developer’s Twitter page.
“Sputnik V has applied for a gradual examination, and a request for approval for the market is the next step,” the statement said.
The developers expect that the EU drug regulator will soon begin the procedure and officially announce it.
In addition, the developers proposed to accelerate the start of large-scale vaccine shipments in the EU by attracting EU manufacturing facilities, which are awaiting EMA approval of the vaccine.
Earlier, EMA said that it had not received an application from the developer of the Russian anti-acid drug to authorize the said drug on the Western market. The Russian Direct Investment Fund (RDIF) responded by issuing a certificate of filing an application for registration in the European Union for the Sputnik V coronavirus vaccine. They also named possible dates for the start of the supply of the Russian drug to the European Union.